| Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs … KI Birkeland, ME Jørgensen, B Carstensen, F Persson, HL Gulseth, ... The lancet Diabetes & endocrinology 5 (9), 709-717, 2017 | 378 | 2017 |
| Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA-and PI3K/Akt-dependent pathways and requires GLP-1 receptor Ö Erdogdu, D Nathanson, Å Sjöholm, T Nyström, Q Zhang Molecular and cellular endocrinology 325 (1-2), 26-35, 2010 | 280 | 2010 |
| Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl … F Persson, T Nyström, ME Jørgensen, B Carstensen, HL Gulseth, ... Diabetes, Obesity and Metabolism 20 (2), 344-351, 2018 | 221 | 2018 |
| Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden … A Norhammar, J Bodegård, T Nyström, M Thuresson, JW Eriksson, ... Diabetologia 59, 1692-1701, 2016 | 142 | 2016 |
| Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality JW Eriksson, J Bodegard, D Nathanson, M Thuresson, T Nyström, ... Diabetes research and clinical practice 117, 39-47, 2016 | 129 | 2016 |
| Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety D Nathanson, B Ullman, U Löfström, A Hedman, M Frick, Å Sjöholm, ... Diabetologia 55, 926-935, 2012 | 120 | 2012 |
| Exendin-4 reduces ischemic brain injury in normal and aged type 2 diabetic mice and promotes microglial M2 polarization V Darsalia, S Hua, M Larsson, C Mallard, D Nathanson, T Nystroem, ... PloS one 9 (8), e103114, 2014 | 99 | 2014 |
| Novel oral glucose‐lowering drugs are associated with lower risk of all‐cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with … T Nyström, J Bodegard, D Nathanson, M Thuresson, A Norhammar, ... Diabetes, Obesity and Metabolism 19 (6), 831-841, 2017 | 95 | 2017 |
| Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE‐TIMI 58 trial: a nationwide observational study A Norhammar, J Bodegård, T Nyström, M Thuresson, D Nathanson, ... Diabetes, Obesity and Metabolism 21 (5), 1136-1145, 2019 | 84 | 2019 |
| Hypoglycemic pharmacological treatment of type 2 diabetes: targeting the endothelium D Nathanson, T Nyström Molecular and cellular endocrinology 297 (1-2), 112-126, 2009 | 81 | 2009 |
| Endothelial dysfunction induced by triglycerides is not restored by exenatide in rat conduit arteries ex vivo D Nathanson, Ö Erdogdu, J Pernow, Q Zhang, T Nyström Regulatory peptides 157 (1-3), 8-13, 2009 | 69 | 2009 |
| Differences in associations of antidepressants and hospitalization due to hyponatremia S Farmand, JD Lindh, J Calissendorff, J Skov, H Falhammar, ... The American journal of medicine 131 (1), 56-63, 2018 | 65 | 2018 |
| Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events … T Nyström, J Bodegard, D Nathanson, M Thuresson, A Norhammar, ... diabetes research and clinical practice 123, 199-208, 2017 | 56 | 2017 |
| Type 2 diabetes impairs odour detection, olfactory memory and olfactory neuroplasticity; effects partly reversed by the DPP-4 inhibitor Linagliptin G Lietzau, W Davidsson, CG Östenson, F Chiazza, D Nathanson, ... Acta neuropathologica communications 6, 1-15, 2018 | 51 | 2018 |
| Associations of proton pump inhibitors and hospitalization due to hyponatremia: a population–based case–control study H Falhammar, JD Lindh, J Calissendorff, J Skov, D Nathanson, ... European Journal of Internal Medicine 59, 65-69, 2019 | 50 | 2019 |
| Glucagon-like receptor 1 agonists and DPP-4 inhibitors: potential therapies for the treatment of stroke V Darsalia, M Larsson, D Nathanson, T Klein, T Nyström, C Patrone Journal of Cerebral Blood Flow & Metabolism 35 (5), 718-723, 2015 | 47 | 2015 |
| Effect of flash glucose monitoring in adults with type 1 diabetes: a nationwide, longitudinal observational study of 14,372 flash users compared with 7691 glucose sensor naive … D Nathanson, AM Svensson, M Miftaraj, S Franzén, J Bolinder, ... Diabetologia 64, 1595-1603, 2021 | 46 | 2021 |
| Cardiovascular and renal disease burden in type 1 compared with type 2 diabetes: a two-country nationwide observational study R Kristófi, J Bodegard, A Norhammar, M Thuresson, D Nathanson, ... Diabetes Care 44 (5), 1211-1218, 2021 | 45 | 2021 |
| Differences in associations of antiepileptic drugs and hospitalization due to hyponatremia: A population–based case–control study H Falhammar, JD Lindh, J Calissendorff, S Farmand, J Skov, ... Seizure 59, 28-33, 2018 | 45 | 2018 |
| Gliptin‐mediated neuroprotection against stroke requires chronic pretreatment and is independent of glucagon‐like peptide‐1 receptor V Darsalia, M Larsson, G Lietzau, D Nathanson, T Nyström, T Klein, ... Diabetes, Obesity and Metabolism 18 (5), 537-541, 2016 | 45 | 2016 |
NorhammarKarolinska Institutet在 norhammar.se 的电子邮件经过验证
